{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:51:37Z","timestamp":1784886697171,"version":"3.55.0"},"reference-count":43,"publisher":"Impact Journals, LLC","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,5,16]]},"DOI":"10.18632\/oncotarget.10592","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T04:34:39Z","timestamp":1468470879000},"page":"32450-32460","source":"Crossref","is-referenced-by-count":43,"title":["Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy"],"prefix":"10.18632","volume":"8","author":[{"given":"Chunguang","family":"Wang","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892, USA"},{"name":"Department of Thoracic Surgery, Second Hospital of Jilin University, Changchun, 130041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892, USA"},{"name":"Key Laboratory of Human Functional Genomics of Jiangsu Province, Department of Cell Biology, School of Basic Medical Science, Nanjing Medical University, Nanjing, Jiangsu, 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqian","family":"Feng","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Ho","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,7,13]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","article-title":"Primary liver cancer: worldwide incidence and trends","volume":"127","author":"Cleries","year":"2004","journal-title":"Gastroenterology"},{"key":"2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1634\/theoncologist.2010-S4-42","article-title":"Treatment of intermediate\/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?","volume":"15","author":"Venook","year":"2010","journal-title":"Oncologist"},{"key":"3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-16037-0_1","article-title":"Hepatocellular carcinoma biology","volume":"190","author":"Mishra","year":"2013","journal-title":"Recent Results Cancer Res"},{"key":"4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival","volume":"37","author":"Bruix","year":"2003","journal-title":"Hepatology"},{"key":"5","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Bruix","year":"2003","journal-title":"Lancet"},{"key":"6","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jhep.2011.07.031","article-title":"Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?","volume":"56","author":"Meyer","year":"2012","journal-title":"J Hepatol"},{"key":"7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Zeuzem","year":"2008","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1872-034X.2012.01113.x","article-title":"Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update","volume":"43","author":"Ho","year":"2013","journal-title":"Hepatol Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Kreitman","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1078\/1438-4221-00302","article-title":"Recombinant immunotoxins for treating cancer","volume":"293","author":"Pastan","year":"2004","journal-title":"Int J Med Microbiol"},{"key":"11","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1200\/JCO.2008.20.2630","article-title":"Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia","volume":"27","author":"Pastan","year":"2009","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Pastan","year":"2001","journal-title":"N Engl J Med"},{"key":"13","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Pastan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"14","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P","volume":"15","author":"Pastan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"15","first-page":"208ra147","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Pastan","year":"2013","journal-title":"Sci Transl Med"},{"key":"16","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/0008-5472.CAN-11-1374","article-title":"Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates","volume":"71","author":"Pastan","year":"2011","journal-title":"Cancer Res"},{"key":"17","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood-2008-08-173195","article-title":"A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity","volume":"113","author":"Pastan","year":"2009","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"11782","DOI":"10.1073\/pnas.1209292109","article-title":"Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes","volume":"109","author":"Pastan","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-12-0336","article-title":"A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity","volume":"12","author":"Pastan","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"20","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1158\/1535-7163.MCT-14-0132","article-title":"Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers","volume":"13","author":"Pastan","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"21","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1158\/1535-7163.MCT-14-0089-T","article-title":"In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer","volume":"13","author":"Pastan","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejca.2010.10.024","article-title":"Glypican-3: a new target for cancer immunotherapy","volume":"47","author":"Kim","year":"2011","journal-title":"Eur J Cancer"},{"key":"23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/11595360-000000000-00000","article-title":"Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin","volume":"25","author":"Ho","year":"2011","journal-title":"BioDrugs"},{"key":"24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.febslet.2013.10.002","article-title":"Glypican-3 antibodies: a new therapeutic target for liver cancer","volume":"588","author":"Ho","year":"2014","journal-title":"FEBS Lett"},{"key":"25","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1349-7006.2009.01206.x","article-title":"Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma","volume":"100","author":"Nakatsura","year":"2009","journal-title":"Cancer Sci"},{"key":"26","first-page":"14","article-title":"The role of glypican-3 in regulating Wnt in hepatocellular carcinomas","volume":"1","author":"Ho","year":"2011","journal-title":"Cancer Rep"},{"key":"27","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.26996","article-title":"Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy","volume":"60","author":"Ho","year":"2014","journal-title":"Hepatology"},{"key":"28","doi-asserted-by":"crossref","first-page":"e0137664","DOI":"10.1371\/journal.pone.0137664","article-title":"Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells","volume":"10","author":"Ho","year":"2015","journal-title":"PLoS One"},{"key":"29","doi-asserted-by":"crossref","first-page":"6536","DOI":"10.1038\/ncomms7536","article-title":"Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis","volume":"6","author":"Ho","year":"2015","journal-title":"Nat Commun"},{"key":"30","doi-asserted-by":"crossref","first-page":"592","DOI":"10.4161\/mabs.20933","article-title":"High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening","volume":"4","author":"Ho","year":"2012","journal-title":"MAbs"},{"key":"31","first-page":"136","article-title":"SK HEP-1: a human cell line of endothelial origin","volume":"28A","author":"Darlington","year":"1992","journal-title":"Cell Dev Biol"},{"key":"32","doi-asserted-by":"crossref","first-page":"E1083","DOI":"10.1073\/pnas.1217868110","article-title":"Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma","volume":"110","author":"Ho","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Pastan, Ho. Recombinant Immunotoxins for Treating Cancer. Antibody Engineering. 2 (2nd ed). 2010; 127\u2013146.","DOI":"10.1007\/978-3-642-01147-4_10"},{"key":"34","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1634\/theoncologist.2015-0057","article-title":"Targeting the WNT Signaling Pathway in Cancer Therapeutics","volume":"20","author":"Lieu","year":"2015","journal-title":"Oncologist"},{"key":"35","first-page":"2311","article-title":"Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor","volume":"5","author":"Pastan","year":"1999","journal-title":"Clin Cancer Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.3748\/wjg.14.6437","article-title":"Evolution of systemic therapy of advanced hepatocellular carcinoma","volume":"14","author":"Poon","year":"2008","journal-title":"World J Gastroenterol"},{"key":"37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/jpet.110.175786","article-title":"Activation of phosphatidylinositol 3-kinase\/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells","volume":"337","author":"Cheng","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jhep.2012.02.019","article-title":"Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells","volume":"57","author":"Desbois-Mouthon","year":"2012","journal-title":"J Hepatol"},{"key":"39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0192-0561(91)90112-K","article-title":"Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion","volume":"13","author":"Pastan","year":"1991","journal-title":"I Int J Immunopharmacol"},{"key":"40","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ijc.2910620320","article-title":"Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice","volume":"62","author":"Pastan","year":"1995","journal-title":"Int J Cancer"},{"key":"41","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.leukres.2014.06.014","article-title":"An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies","volume":"38","author":"Pastan","year":"2014","journal-title":"Leuk Res"},{"key":"42","first-page":"4018","article-title":"Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2","volume":"59","author":"Pastan","year":"1999","journal-title":"Cancer Res"},{"key":"43","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1073\/pnas.1405153111","article-title":"Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes","volume":"111","author":"Benhar","year":"2014","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T18:50:38Z","timestamp":1589136638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,13]]},"references-count":43,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2017,5,16]]}},"alternative-id":["10592","27419635"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.10592","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,13]]}}}